Related Experiment Video
Updated: Jun 24, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Optimus-Era Dose Finding for Rare Cancers
Yonina R Murciano-Goroff1, Sean M Devlin1, Alexia Iasonos1
1Memorial Sloan Kettering Cancer Center, New York, New York.
Summary:
Advances in cancer biology and diagnostics have led to the recognition of a multitude of rare cancer subtypes, emphasizing the pressing need for strategies to accelerate drug development for patients with these cancers. This paper addresses the unique challenges of dose finding in trials that accrue small numbers of patients with rare cancers; strategies for dose optimization are proposed, in line with evolving approaches to dose determination in the age of the US Food and Drug Administration's Project Optimus.
Insights
Developing new cancer drugs is hard for rare subtypes. This study proposes dose-finding strategies for small patient groups, aligning with FDA Project Optimus guidelines.
Area of Science:
- Oncology
- Clinical Pharmacology
- Drug Development
Background:
- Growing recognition of rare cancer subtypes necessitates accelerated drug development.
- Small patient populations in rare cancers present unique challenges for clinical trials.
Purpose of the Study:
- To address the challenges of dose finding in rare cancer clinical trials.
- To propose strategies for dose optimization in rare cancers.
- To align dose-finding approaches with the US Food and Drug Administration's Project Optimus.
Main Methods:
- Review of current dose-finding methodologies.
- Analysis of challenges specific to rare cancer trials.
- Proposal of adaptive and innovative dose optimization strategies.
Main Results:
- Identified key dose-finding challenges in rare cancer trials.
- Outlined practical strategies for optimizing drug dosage in small patient cohorts.
- Provided a framework for dose determination aligned with Project Optimus.
Conclusions:
- Effective dose finding in rare cancers requires tailored strategies.
- Proposed methods facilitate efficient drug development for rare cancer patients.
- Alignment with Project Optimus ensures modern, optimized dose determination.
More Related Videos
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
